Advertisement
Canada markets close in 3 hours 21 minutes
  • S&P/TSX

    21,771.01
    +62.57 (+0.29%)
     
  • S&P 500

    4,967.28
    -43.84 (-0.87%)
     
  • DOW

    37,837.25
    +61.87 (+0.16%)
     
  • CAD/USD

    0.7269
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    82.96
    +0.23 (+0.28%)
     
  • Bitcoin CAD

    87,683.19
    -59.12 (-0.07%)
     
  • CMC Crypto 200

    1,370.89
    +58.27 (+4.44%)
     
  • GOLD FUTURES

    2,406.40
    +8.40 (+0.35%)
     
  • RUSSELL 2000

    1,939.25
    -3.71 (-0.19%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,315.18
    -286.32 (-1.84%)
     
  • VOLATILITY

    18.96
    +0.96 (+5.33%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Better Buy: AbbVie vs. Johnson & Johnson

Better Buy: AbbVie vs. Johnson & Johnson

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.